Skip to main content

Table 2 Studies reporting adjusted odds ratios for mortality in urinary LAM-positive compared to urinary LAM-negative TB cases, after adjustment for other predictors of mortality

From: Detection of lipoarabinomannan (LAM) in urine is an independent predictor of mortality risk in patients receiving treatment for HIV-associated tuberculosis in sub-Saharan Africa: a systematic review and meta-analysis

Study

Study setting and population

Adjusted odds ratio for mortality in urinary LAM-positive compared to urinary LAM-negative TB cases (95 % CI)

Variables included in the multivariable analysis with urinary LAM status

Talbot et al. (2012) [49]

Hospital inpatients; TB suspected

1.3 (0.9–1.8)

CD4 cell count, ART

Drain et al. (2015) [52]

Outpatients; confirmed TB patients

5 (1.1–23.9)

CD4 cell count, age, gender, Karnofsky score

Peter et al. (2015) [53]

Hospital inpatients; TB suspected

4.7 (1.6–15.9)

Study site, gender, age, CD4 cell count

Lawn et al. (2015) [54]

Hospital inpatients; All HIV+ patients

4.2 (1.5–11.8)

Age, CD4 cell count

Bjerrum et al. (2015) [55]

Hospital inpatients and outpatients; TB suspected

2.2 (1.1–3.5)

Gender, hospitalisation, CD4 cell count, Medical Early Warning Score

  1. ART antiretroviral therapy, CI confidence interval, LAM lipoarabinomannan, TB tuberculosis